Myasthenia gravis (MG) is a human autoimmune disease mediated by anti-acetylcholine receptor (AChR) antibodies. The thymus is probably the site where the autoimmune response is triggered and maintained. Recent reports have linked various autoimmune disease with defective Fas expression. We thus analyzed Fas expression in thymocytes and peripheral blood lymphocytes (PBL) from MG patients. The proportion of a thymocyte subpopulation with strong Fas expression (Fashi) was markedly enhanced in MG patients with anti-AChR antibodies (P < .0003, compared with controls). In this group of patients, the proportion of CD4+Fashi and CD4+CD8+Fashi thymocytes were significantly increased (P < .002 for both subsets). Fashi thymocytes were enriched in activated cells and showed intermediate CD3 expression. They were preferentially Vβ5.1-expressing cells, previously shown to be enriched in potentially autoreactive cells. The proliferative response of thymocytes from MG patients to peptides from the AChR was abolished after depletion of Fashi cells. Fashi thymocytes were sensitive to an agonistic anti-Fas antibody. In peripheral blood, Fashi lymphocytes proportion was not significantly modified in MG patients whatever their anti-AChR antibody titer, compared with controls. Altogether, these results indicate that Fashi thymocytes, which accumulate in MG patients with anti-AChR antibodies, could be involved in the autoimmune response that targets the AChR.

MYASTHENIA GRAVIS (MG) is an autoimmune disease characterized by antibodies that target the acetylcholine receptor (AChR) at the neuromuscular junction and that are present in more than 85% of patients.1 These autoantibodies are produced under the control of major histocompatibility class (MHC) II-restricted CD4+ helper T lymphocytes. Several arguments suggest a relationship between MG and the thymus: (1) MG is often associated with morphologic thymus abnormalities.2 10% to 15% of patients have thymomas and 50% to 60% have hyperplasia; these are characterized by the presence of lymphoid follicles with germinal centers and are found in young patients with high titers of anti-AChR antibodies3; (2) thymectomy has a beneficial effect4,5; (3) after thymectomy of MG patients, both anti-AChR antibody titers6 and in vitro production of anti-AChR antibodies from stimulated peripheral blood lymphocyte (PBL)7 decrease; (4) isolated thymocytes from MG patients can produce anti-AChR antibodies spontaneously8,9; (5) AChR-reactive T cells are present in the thymus of MG patients10,11; and (6) T lymphocytes12 and B lymphocytes13 from MG thymuses are activated. Altogether these arguments indicate that the thymus is probably the site where the autoimmune response is triggered and maintained.

During intrathymic development, programmed cell death appears to be an important option at several stages. A large number of immature thymocytes die because they fail to express a T-cell receptor (TCR) with sufficient affinity for thymic MHC molecules. Cells that are not positively selected may die from “neglect”14 and may constitute the bulk of cells that die of apoptosis in the thymus.15 The same mechanism of cell death underlies the deletion of autoreactive immature thymocytes.16 Thymocytes bearing autoreactive TCR with a high affinity for MHC molecules and specific peptide presented by stromal cells in the thymus undergo negative selection by apoptosis, whereas cells with lower affinity can further differentiate into mature CD4+ or CD8+ cells strongly expressing TCR. In addition, some autoreactive single-positive CD4+ or CD8+ cells are deleted in the periphery.17 

It has been suggested that autoimmune disease is caused by a failure to eliminate self-reactive lymphocytes, essentially in the periphery, and also by defective apoptosis. In three different strains of mice that develop a disease analogous to human lupus, abnormalities have been detected in the Fas and Fas ligand genes, whose protein products interact to mediate apoptosis.18 Elevated serum concentrations of a soluble form of the Fas receptor that is able to inhibit Fas-mediated apoptosis have been found in human systemic lupus erythematosus19 and Fas antigen expression is increased in peripheral lymphocytes.20-22 Recent studies have linked defective Fas-mediated T-lymphocyte apoptosis to various Fas gene mutations in a human autoimmune lymphoproliferative syndrome.23 24 

In the immune system, the Fas/Fas ligand system is involved in two mechanisms: T-cell cytotoxicity25 and activation-induced cell death.26-28 The involvement of Fas in thymic apoptosis (and particularly in negative selection) is controversial. In lpr mice, in which systemic autoimmune disease is related to a Fas gene defect,29 and in Fas-null mice, negative selection is normal in the thymus while activation-induced cell death of activated peripheral lymphocytes is impaired.30,31 However, an accumulation of immature cells (CD4+CD8+TCRlow) resistant to apoptosis has been described in the thymus of lpr mice.32 Mariani et al33 have reported that Fas expression is 10 times lower in the lpr mouse thymus than in control animals; this low expression could be sufficient for adequate programmed cell death of autoreactive cells. Furthermore, agonistic anti-Fas antibody was able to induce mouse thymocyte apoptosis in the presence of additional signals: metabolic inhibitors34 or TCR stimulation.35 

MG is a human autoimmune disease in which the autoantigen (AChR) is well characterized. Recent reports have linked various autoimmune diseases to defective Fas-mediated apoptosis or Fas expression. This raises the possibility that such abnormalities could be involved in the pathogenesis of MG. Because the thymus is clearly involved in MG, we analyzed Fas expression in thymocytes and also in PBL from patients with MG.

Patients.We studied 31 patients with myasthenia gravis (28 females and 3 males, ages 8 to 48 years) who were undergoing thymectomy at Marie-Lannelongue Hospital. Table 1 summarizes the following clinical characteristics: age, sex, disease severity, thymic histology, anti-AChR antibody titer, time since onset, and concomitant treatments. Disease severity was evaluated using Osserman's classification (I: ocular symptoms; IIA: generalized without bulbar symptoms; IIB: generalized with bulbar symptoms). Fresh thymic tissue was obtained in aseptic conditions. No thymocytes could be obtained from 5 patients because the thymus was too involuted. Patients with thymomas were excluded from the study. Thymic hyperplasia was defined according to the classification of Levine and Rosai36 as thymuses containing germinal centers, and was found in 19 patients (6 with few germinal centers, 13 with a large number of germinal centers). Twelve patients had a normal or involuted thymus. All the patients were on anticholinesterase treatment and 4 were on steroids and immunosuppressive drugs. Three groups of patients were distinguished according to the anti-AChR antibody titer: high titer > 10 nmol/L (10 patients); intermediate titer, 1 to 10 nmol/L (11 patients), and negative or borderline titer, <1 nmol/L (10 patients). Anti-AChR antibody titers were determined in serum as previously described.37 38 

Table 1.

Characteristics of the Patients Studied

No. of PatientsFrequency (%)
Sex 
Female 28 90 
Male 10 
Age 
≤35 yr 22 71 
>35 yr 29 
Onset 
≤1 yr 13 42 
>1 yr 18 58 
Severity grade 
IIA 13 
IIB 25 81 
Thymus histology 
Normal or involuted 12 39 
Hyperplasia + 19 
Hyperplasia ++ 13 42 
Steroid treatment 
No 27 88 
Yes 12 
Anti-AChR Ab titers (nmol/L) 
<1 10 32 
1-10 11 36 
>10 10 32 
No. of PatientsFrequency (%)
Sex 
Female 28 90 
Male 10 
Age 
≤35 yr 22 71 
>35 yr 29 
Onset 
≤1 yr 13 42 
>1 yr 18 58 
Severity grade 
IIA 13 
IIB 25 81 
Thymus histology 
Normal or involuted 12 39 
Hyperplasia + 19 
Hyperplasia ++ 13 42 
Steroid treatment 
No 27 88 
Yes 12 
Anti-AChR Ab titers (nmol/L) 
<1 10 32 
1-10 11 36 
>10 10 32 

Blood from the same patients (except for 8 patients) was collected just before thymectomy, and PBL were isolated over Ficoll gradients.

Normal thymuses were obtained from young adults (age range, from 10 to 25 years) undergoing heart surgery. Blood from healthy adult volunteers was also used in control experiments.

Thymocyte isolation and selection.Thymocytes were mechanically isolated by gently scraping fresh thymic tissue, filtering the cells through sterile gauze, and washing them once in Hanks' balanced salt solution (HBSS). When the quantity of cells (counted by using the Trypan blue dye exclusion method) was sufficient, aliquots of 20 million cells were stored in liquid nitrogen.

In some experiments, cells were thawed and CD8-depleted thymocytes were isolated. After washing, total thymocytes were mixed with anti-CD8 magnetic beads (Immunotech, Marseille, France) in phosphate-buffered saline (PBS)-30% human AB serum to separate CD8+ cells. Anti-Fas antibody (UB2) was fixed on goat-antimouse–coated magnetic beads (Immunotech) following the manufacturer's instructions. Using these beads CD8-depleted thymocytes were depleted in Fashi cells. CD8-depleted cells and CD8- and Fashi-depleted cells were cultured (0.2 × 106 cells/200 μL/well) in RPMI 1640 medium supplemented with 2 mmol/L L-glutamine, 25 mmol/L HEPES, 100 IU/mL penicillin, 100 μg/mL streptomycin, and 2% human AB serum in the absence or in the presence of peptides (5 μg/mL) from the AChR α-subunit, p168-181 (1H) or p351-368 (3H). After a 6-day culture period, 1 μCi of 3H-thymidine (NEN, Les Ulis, France; 6.7 Cie/mmol) was added to each well. After 20 hours, cells were obtained and 3H-thymidine incorporation was determined by counting the radioactivity on filters. Cultures were performed in 4 to 8 samples.

Immunofluorescence studies.Thymocytes and PBL were labeled with the following monoclonal fluorochrome-coupled antibodies (Immunotech): anti-CD4, anti-CD8, anti-CD3, anti-CD25, and anti–HLA-DR. FITC-anti Vβ5.1 (LC4 clone) and FITC-anti Vβ6.7 (OT145 clone) were obtained from T Cell Sciences Inc (Cambridge, MA). Three-color flow cytometry was used to examine the relationship between Fas and other markers. PBL and thymocytes (106) were first incubated with anti-Fas (anti-CD95) monoclonal antibody (clone UB2; Immunotech) for 30 minutes at 4°C, then washed twice in HBSS supplemented with 5% fetal calf serum (FCS), stained with goat-antimouse IgG antibody, washed twice, and incubated with Cy-chrome-labeled streptavidin (Pharmingen, San Diego, CA) and membrane fluorescein (FITC)- or phycoerythrin (PE)-coupled antibodies.

Cell labeling was analyzed on a FACScan flow cytometer (Becton Dickinson, Grenoble, France) using Lysis II software that allows the analysis of data obtained with a Becton Dickinson flow cytometer. A gate was set on intact cells using forward- and side-scatter analysis; 104 cells were analyzed in this gate.

Thymocyte culture and anti-Fas antibody assay.After the isolation of thymic cells, 0.5 × 106 were cultured in the presence of 5 μg/mL anti-Fas antibody (clone CH-11; Immunotech) immobilized on 96-well plates, in RPMI 1640 medium supplemented with 10% FCS, 2 mmol/L L-glutamine, 25 mmol/L HEPES, 100 IU/mL penicillin, and 100 μg/mL streptomycin. After 18 hours the cells were harvested and labeled; Fas expression was analyzed as previously described.

Statistical analysis.Differences between groups were compared by using the Mann-Whitney or Wilcoxon test (Instat; Graph Pad Software, San Diego, CA). A difference was considered significant if the P value was below .05.

Thymocytes with strong Fas expression (Fashi) accumulate in MG patients with positive anti-AChR antibody titers.Fas expression was compared between thymuses from control subjects and MG patients by using immunofluorescence on freshly isolated thymocytes (Fig 1). In all the thymuses (Fig 1A) about 90% of thymocytes displayed low Fas expression (Faslo). In age-matched control thymuses a small proportion of thymocytes (0.4% to 2.8%) showed strong Fas expression (Fashi). The major peak of fluorescence was composed of Faslo cells. A second peak, at the end of the major peak, was composed of Fashi cells; its fluorescence level was above 102. In thymuses from patients with negative or borderline anti-AChR antibody titers (<1 nmol/L), the proportion of Fashi thymocytes was not significantly different from control values (1.3% ± 0.2% v 1.5% ± 0.3% in controls). By contrast, MG patients with positive titers (≥1 nmol/L) had far higher proportions of Fashi thymocytes (0.7% to 14.2% of total thymocytes; mean 5.6% ± 0.7%; P < .0003 compared to controls and P < .0001 compared to patients with negative or borderline titers (Fig 1B). Furthermore, this increase in the proportion of Fashi cells correlated with the autoantibody titer (4.1% ± 0.7% in thymuses from MG patients with an intermediate titer, P < .006 compared to controls; and 7.0% ± 1.1% in thymuses from MG patients with a high titer, P < .0004 compared to controls).

Fig. 1.

Comparison of Fas expression in thymocytes from controls and MG patients. Freshly isolated thymocytes were stained with anti-Fas antibody, then with goat-antimouse IgG antibody, and finally with Cy-chrome-labeled streptavidin. Using the Lysis II program, a marker was set to define the proportion of Fashi thymocytes. (A) Representative analysis of one control and three MG thymuses. The percentage of Fashi thymocytes is indicated, as well as age and the anti-AChR antibody titer (nmol/L). Fas expression is clearly increased in patients with positive anti-AChR antibody titers (MG2 and MG3) but not in the patient with a negative titer (MG1). (B) The proportion of Fashi thymocytes was determined in 26 MG patients and 7 control subjects. Two groups of patients (anti-AChR antibody titer < 1 nmol/L and ≥1 nmol/L) are distinguished and compared with controls by using the Mann-Whitney test. The bar represents the mean value. Only the group of patients with positive anti-AChR antibody titers differed from the controls.

Fig. 1.

Comparison of Fas expression in thymocytes from controls and MG patients. Freshly isolated thymocytes were stained with anti-Fas antibody, then with goat-antimouse IgG antibody, and finally with Cy-chrome-labeled streptavidin. Using the Lysis II program, a marker was set to define the proportion of Fashi thymocytes. (A) Representative analysis of one control and three MG thymuses. The percentage of Fashi thymocytes is indicated, as well as age and the anti-AChR antibody titer (nmol/L). Fas expression is clearly increased in patients with positive anti-AChR antibody titers (MG2 and MG3) but not in the patient with a negative titer (MG1). (B) The proportion of Fashi thymocytes was determined in 26 MG patients and 7 control subjects. Two groups of patients (anti-AChR antibody titer < 1 nmol/L and ≥1 nmol/L) are distinguished and compared with controls by using the Mann-Whitney test. The bar represents the mean value. Only the group of patients with positive anti-AChR antibody titers differed from the controls.

Close modal

Activation state of Fashi thymocytes.We first compared the activation state of Fashi and Faslo cells by means of two-color immunofluorescence with anti-Fas and anti–interleukin-2 (IL-2) receptor α (anti-CD25) antibodies or anti-Fas and anti–HLA-DR antibodies on freshly isolated thymocytes from 6 MG patients and 6 control subjects. A representative analysis of 1 MG patient is presented in Fig 2A. In MG patients (Fig 2B), a higher proportion of Fashi thymocytes expressed the IL-2 receptor α and HLA-DR, relative to Faslo thymocytes. Similar results were obtained in controls (Fig 2B).

Fig. 2.

Activation state of Faslo and Fashi thymocytes. Freshly isolated thymocytes were stained with anti-Fas antibody and PE-labeled anti-CD25 or FITC-labeled anti-HLA-DR. (A) In Fas expression analysis, gates were set to define Faslo and Fashi thymocytes. During the acquisition step, events were accumulated in these gates. Analysis of one representative MG patient (anti-AChR antibody titer 33 nmol/L) is shown. In this representative analysis (one of six experiments) the percentage of HLA-DR–expressing or CD25-expressing cells is strikingly higher in Fashi thymocytes than in Faslo thymocytes. (B) Such analyses were performed on 6 controls and 6 MG patients. Data presented are mean ± SEM. The increase in HLA-DR or CD25+ cells in Fashi thymocytes compared with Faslo thymocytes were similar in controls and in MG patients.

Fig. 2.

Activation state of Faslo and Fashi thymocytes. Freshly isolated thymocytes were stained with anti-Fas antibody and PE-labeled anti-CD25 or FITC-labeled anti-HLA-DR. (A) In Fas expression analysis, gates were set to define Faslo and Fashi thymocytes. During the acquisition step, events were accumulated in these gates. Analysis of one representative MG patient (anti-AChR antibody titer 33 nmol/L) is shown. In this representative analysis (one of six experiments) the percentage of HLA-DR–expressing or CD25-expressing cells is strikingly higher in Fashi thymocytes than in Faslo thymocytes. (B) Such analyses were performed on 6 controls and 6 MG patients. Data presented are mean ± SEM. The increase in HLA-DR or CD25+ cells in Fashi thymocytes compared with Faslo thymocytes were similar in controls and in MG patients.

Close modal

Fashi thymocytes in intrathymic differentiation.The three-color immunofluorescence technique was used to investigate the maturation step at which the proportion of Fashi thymocytes was enhanced. We first analyzed CD4 and CD8 expression in the whole thymocyte population. In MG patients with negative or borderline anti-AChR antibody titers, the proportion of single-positive CD4+ and CD8+, of double-positive CD4+CD8+, and double-negative CD4CD8 cells were not modified (Fig 3A). In patients with positive anti-AChR antibody titers, the proportion of CD4+ and double-positive cells were significantly enhanced and decreased, respectively, as previously described.39 The significative increase in the proportion of double-negative thymocytes was associated with an increase in percentage of B cells in hyperplastic thymuses as previously shown.13 39 We then analyzed Fas expression in single-positive CD4+ and CD8+, doublepositive CD4+CD8+, and double-negative CD4CD8 cells from all the patients' thymuses and calculated the proportion of CD4+Fashi, CD4+CD8+Fashi, CD8+Fashi, and CD4CD8Fashi thymocytes among the whole cell population (Fig 3B). In patients with positive anti-AChR antibody titer, but not in patients with negative or borderline titer, the proportion of CD4+Fashi and CD4+CD8+Fashi thymocytes were significantly increased, relative to the control subjects (P < .002 for both subsets). No significant increase was observed in CD8+Fashi cells, whatever the anti-AChR antibody titer. In patients with positive anti-AChR antibody titers, the significative increase in double-negative Fashi thymocytes was related to the presence of B cells in this population; indeed, the proportion of Fashi cells was about 30% of total thymic B cells (data not shown).

Fig. 3.

Proportion of FashiCD4+, FashiCD8+, FashiCD4+ CD8, and FashiCD4CD8 thymocytes among the whole population. (A) CD4 and CD8 expression was first analyzed in 7 controls and 26 MG patients. Data are mean ± SEM. As in Fig 1, two groups were distinguished according to their anti-AChR antibody titer: negative or borderline (<1 nmol/L) and positive (≥1 nmol/L). In this last group, CD4+ and double-negative cell proportions were significantly increased whereas the proportion of double-positive cells was significantly decreased, compared with controls. Using three-color immunofluorescence, Fas expression was analyzed in each population (CD4+, CD8+, CD4+CD8+, and CD4CD8); it allowed us to calculate the proportions of FashiCD4+, FashiCD8+, FashiCD4+CD8+, and FashiCD4CD8 thymocytes among the whole population. Differences were compared using the Mann-Whitney test. In the group of patients with positive anti-AChR antibody titers, the percentages of FashiCD4 and Fashi CD4+CD8+ were significantly increased relative to controls.

Fig. 3.

Proportion of FashiCD4+, FashiCD8+, FashiCD4+ CD8, and FashiCD4CD8 thymocytes among the whole population. (A) CD4 and CD8 expression was first analyzed in 7 controls and 26 MG patients. Data are mean ± SEM. As in Fig 1, two groups were distinguished according to their anti-AChR antibody titer: negative or borderline (<1 nmol/L) and positive (≥1 nmol/L). In this last group, CD4+ and double-negative cell proportions were significantly increased whereas the proportion of double-positive cells was significantly decreased, compared with controls. Using three-color immunofluorescence, Fas expression was analyzed in each population (CD4+, CD8+, CD4+CD8+, and CD4CD8); it allowed us to calculate the proportions of FashiCD4+, FashiCD8+, FashiCD4+CD8+, and FashiCD4CD8 thymocytes among the whole population. Differences were compared using the Mann-Whitney test. In the group of patients with positive anti-AChR antibody titers, the percentages of FashiCD4 and Fashi CD4+CD8+ were significantly increased relative to controls.

Close modal

In the same labeling experiments we examined CD4 and CD8 markers in Fashi thymocytes from MG patients and controls to characterize their maturation state. As previously described by Debatin et al,40 Faslo cells had a CD4/CD8 profile similar to that of the total thymocyte population. By contrast, Fashi cells were mainly in the CD4 lineage, ie, CD4+ and CD4+CD8+ cells in MG patients and in control subjects (data not shown). Thymocytes were also simultaneously labeled with anti-Fas and anti-CD3 antibodies. Although Faslo thymocytes showed a wide range of CD3 expression, Fashi thymocytes uniformly showed intermediate CD3 (CD3int) expression (ie, between low and high). The same characteristics were found in control thymuses. Three representative analyses from three MG patients with no anti-AChR antibody, with an intermediate anti-AChR antibody titer, and with a high titer are shown (Fig 4). CD3intFashi thymocyte proportion was all the more increased as the patients' antibody titer was high.

Fig. 4.

Phenotypic characterization of Fashi thymocytes in three representative analyses of MG patients (anti-AChR antibody titer: 0, 3, and 37 nmol/L). Cells were stained with anti-Fas and FITC-labeled CD3. Fashi thymocytes uniformly display an intermediate level of CD3 expression.

Fig. 4.

Phenotypic characterization of Fashi thymocytes in three representative analyses of MG patients (anti-AChR antibody titer: 0, 3, and 37 nmol/L). Cells were stained with anti-Fas and FITC-labeled CD3. Fashi thymocytes uniformly display an intermediate level of CD3 expression.

Close modal

T-cell repertoire in Fashi thymocytes.In previous analyses of TCR Vβ gene segments in thymic cells, we found that the percentage of Vβ5.1-expressing cells, but not that of cells expressing Vβ6.7, was increased in MG patients39,41; this increase involved both mature single-positive thymocytes and their CD3++CD4+CD8+ late precursors. This study suggested a bias in intrathymic selection. In addition, expansion of Vβ5.1-expressing cells was observed in the presence of selected peptides from the AChR α subunit in CD4+ mature thymocytes from MG patients; Vβ5.1-expressing cells were thus enriched in potentially autoreactive cells (Cohen-Kaminsky et al, manuscript submitted, January 1997). We examined the expression of Vβ5.1 and Vβ6.7 in Fashi thymocytes in the present study (Fig 5) in isolated CD4+ thymocytes. This analysis was done on thawed thymocytes from six MG patients, after checking that the Fas expression level was not modified in CD4+ cells by cryopreservation. CD8-depleted thymocytes were selected after separation with magnetic CD8-coated beads. Three-color immunofluorescence analysis showed that the proportion of cells expressing Vβ5.1 was significantly enhanced among CD4+Fashi thymocytes relative to CD4+Faslo cells (P < .04). By contrast, Vβ6.7 expression was not significantly increased among CD4+Fashi thymocytes from MG patients.

Fig. 5.

Comparison of Vβ5.1 and Vβ6.7 expression in CD4+Faslo and CD4+Fashi thymocytes from six MG patients. CD8-depleted thymocytes were labeled with anti-Fas, PE-coupled anti-CD4, FITC-coupled anti-Vβ5.1 or -Vβ6.7. After setting gates to define Faslo and Fashi cells, Vβ5.1 and Vβ6.7 expression was analyzed in these gates and compared by using the Wilcoxon test. Vβ5.1-expressing cells were enriched in Fashi cells compared with Faslo cells, whereas Vβ6.7-expressing cells were equally represented in both populations.

Fig. 5.

Comparison of Vβ5.1 and Vβ6.7 expression in CD4+Faslo and CD4+Fashi thymocytes from six MG patients. CD8-depleted thymocytes were labeled with anti-Fas, PE-coupled anti-CD4, FITC-coupled anti-Vβ5.1 or -Vβ6.7. After setting gates to define Faslo and Fashi cells, Vβ5.1 and Vβ6.7 expression was analyzed in these gates and compared by using the Wilcoxon test. Vβ5.1-expressing cells were enriched in Fashi cells compared with Faslo cells, whereas Vβ6.7-expressing cells were equally represented in both populations.

Close modal

Involvement of Fashi thymocytes in the proliferative response to peptides from the AChR.CD8-depleted and CD8- and Fashi-depleted cells were obtained as previously described. The depletion of Fashi cells targeted around 90% of total CD4+Fashi cells (Fig 6A). CD8-depleted and CD8- and Fashi-depleted cells were cultured in the absence or in the presence of peptides from the AChR. CD4CD8 cells constitute a source of antigen-presenting cells. 1H (169-181) and 3H (351-368) peptides were previously shown to stimulate the proliferative response in MG patient but not in control subject lymphocytes.42 Firstly, thymocytes depleted in Fashi cells spontaneously proliferate less efficiently than CD8-depleted cells in three MG patients (Fig 6B). Secondly, in these patients 1H and/or 3H peptides induce a significant proliferation response in CD8-depleted cells. This response was abrogated when Fashi cells were depleted (Fig 6B). These experiments indicate that cells involved in the proliferative response to peptides from the AChR are Fashi cells.

Fig. 6.

Involvement of Fashi thymocytes in the proliferative response to peptides from the AChR in three MG patients. (A) CD8-depleted thymocytes were labeled with anti-Fas (left). CD8-depleted thymocytes undergoing an additional depletion in Fashi cells were similarly labeled; about 90% of total Fashi cells were depleted (right). (B) After a 6-day period culture in the absence or in the presence of peptides from the AChR (1H and/or 3H, 5 μg/mL) the incorporation of 3H-thymidine (1 μCi for 0.2 × 106 cells during 20 hours) was analyzed and is expressed in counts per minute (means ± SEM from 4 to 8 determinations). When Fashi cells were depleted, the spontaneous proliferation of CD8-depleted cells was abrogated and the proliferative response to AChR peptides is abolished.

Fig. 6.

Involvement of Fashi thymocytes in the proliferative response to peptides from the AChR in three MG patients. (A) CD8-depleted thymocytes were labeled with anti-Fas (left). CD8-depleted thymocytes undergoing an additional depletion in Fashi cells were similarly labeled; about 90% of total Fashi cells were depleted (right). (B) After a 6-day period culture in the absence or in the presence of peptides from the AChR (1H and/or 3H, 5 μg/mL) the incorporation of 3H-thymidine (1 μCi for 0.2 × 106 cells during 20 hours) was analyzed and is expressed in counts per minute (means ± SEM from 4 to 8 determinations). When Fashi cells were depleted, the spontaneous proliferation of CD8-depleted cells was abrogated and the proliferative response to AChR peptides is abolished.

Close modal

Effect of an agonistic anti-Fas antibody on Fashi thymocytes.We have previously found that Fashi thymocytes accumulate in the thymus of MG patients with positive anti-AChR antibody titers. Here we investigated whether the Fas receptor of Fashi cells was functional and whether Fashi cells were eliminated by an agonistic anti-Fas antibody. Immobilized CH-11 anti-Fas (5 μg/mL) was used on freshly isolated thymocytes from three MG patients. Fas and CD3 expression were analyzed after 20 hours of culture. We first checked that Fas staining with UB2 anti-Fas antibody was not blocked or dysregulated in the presence of CH-11 anti-Fas antibody on PBL which were previously shown to be resistant to an agonist antibody during a 1-day culture.43 Human PBL were cultured during 20 hours in the presence of immobilized CH-11 anti-Fas antibody and Fas expression was not significantly modified (data not shown). In MG patients, the proportion of Fashi cells was similar on freshly isolated and cultured thymocytes in control conditions. In the presence of CH-11 anti-Fas antibody the proportion of Fashi thymocytes was reduced by about 80% (Fig 7A). We compared living cell numbers (measured by Trypan blue assay) obtained with and without CH-11 anti-Fas antibody. The total cell number obtained in the presence of CH-11 anti-Fas antibody was not significantly modified compared with control conditions. Cell numbers in CD3intFaslo and CD3intFashi thymocyte populations were calculated from percentages obtained by immunofluorescence analysis. Although CD3intFaslo were not sensitive to an agonist anti-Fas antibody, most CD3intFashi were eliminated in these conditions (Fig 7B).

Fig. 7.

Effect of an agonistic anti-Fas antibody on MG Fashi thymocytes. (A) Fas and CD3 expression was analyzed after 20 hours of culture in the presence of immobilized CH-11 anti-Fas antibody (5 μg/mL) and in control conditions. A representative analysis of an MG patient is shown. After anti-Fas treatment a decrease in the proportion of Fashi thymocytes with intermediate CD3 expression was observed. (B) Living cell numbers (measured by Trypan blue assay) obtained with and without CH-11 anti-Fas antibody were compared in three MG patients. Cell numbers in CD3intFaslo and CD3intFashi thymocytes were calculated from percentages obtained by immunofluorescence analysis. Although CD3intFaslo were not sensitive to CH-11 anti-Fas antibody, most CD3intFashi were eliminated in this condition. Data are the mean ± SEM from three experiments.

Fig. 7.

Effect of an agonistic anti-Fas antibody on MG Fashi thymocytes. (A) Fas and CD3 expression was analyzed after 20 hours of culture in the presence of immobilized CH-11 anti-Fas antibody (5 μg/mL) and in control conditions. A representative analysis of an MG patient is shown. After anti-Fas treatment a decrease in the proportion of Fashi thymocytes with intermediate CD3 expression was observed. (B) Living cell numbers (measured by Trypan blue assay) obtained with and without CH-11 anti-Fas antibody were compared in three MG patients. Cell numbers in CD3intFaslo and CD3intFashi thymocytes were calculated from percentages obtained by immunofluorescence analysis. Although CD3intFaslo were not sensitive to CH-11 anti-Fas antibody, most CD3intFashi were eliminated in this condition. Data are the mean ± SEM from three experiments.

Close modal

Expression of Fas in PBL.Fas expression was analyzed, as described above for thymocytes, on PBL isolated from the same MG patients at the time of thymectomy and from healthy volunteers (Fig 8). We examined the proportion of CD4+ and CD8+ peripheral cells and Fas expression in these subsets, then we calculated the proportion of CD4+Fashi and CD8+Fashi cells among total lymphocytes. CD4+ and CD8+ peripheral cells from controls contained 37.4% ± 0.9% and 32.1% ± 4.8% of Fashi lymphocytes, respectively, in keeping with previous results.44 Whatever the anti-AChR antibody titer of MG patients, the proportion of CD4+Fashi or CD8+Fashi lymphocytes was not significantly modified compared with control subjects. In both groups of MG patients, some individuals (25%) had significant increases (higher than the mean + 2 SD of control values) in the proportion of CD4+Fashi peripheral lymphocytes. A similar result has been obtained with lymphocytes from patients with systemic lupus erythematosus.20 Therefore, there was no major modification in the Fashi cell proportion among peripheral lymphocytes, contrary to thymocytes.

Fig. 8.

Comparison of the proportion of CD4+Fashi and CD8+Fashi cells in control and MG PBL. PBL freshly isolated over Ficoll gradients were stained with anti-Fas, anti-CD4, and anti-CD8 antibodies. The percentage of CD4+ and CD8+ peripheral lymphocytes and the proportion of Fashi cells among these subsets was determined. Two groups of patients (anti-AChR antibody titer <1 nmol/L, ≥1 nmol/L) are distinguished and compared to controls by using the Mann-Whitney test. No significant modification in the proportion of Fashi was observed in MG patient peripheral T-cell subsets.

Fig. 8.

Comparison of the proportion of CD4+Fashi and CD8+Fashi cells in control and MG PBL. PBL freshly isolated over Ficoll gradients were stained with anti-Fas, anti-CD4, and anti-CD8 antibodies. The percentage of CD4+ and CD8+ peripheral lymphocytes and the proportion of Fashi cells among these subsets was determined. Two groups of patients (anti-AChR antibody titer <1 nmol/L, ≥1 nmol/L) are distinguished and compared to controls by using the Mann-Whitney test. No significant modification in the proportion of Fashi was observed in MG patient peripheral T-cell subsets.

Close modal

Dysregulation of Fas expression in MG patients with anti-AChR antibody.The main finding in this study is that Fas antigen expression is dysregulated in thymocytes from patients with myasthenia gravis, a human autoimmune disease, who had positive anti-AChR antibody titer. We showed that thymocytes strongly expressing Fas were present in the thymus of control subjects but at a lower proportion than in MG patients. This is in agreement with reports from Debatin et al40 and Yonehara et al,45 who described, in the normal thymus, a thymocyte subpopulation strongly expressing Fas and representing less than 4% of total thymocytes. This population had the same characteristics in control subjects and MG patients: Fashi thymocytes are enriched in activated cells and are mainly in the CD4 lineage (CD4+ and CD4+CD8+), and express intermediate levels of CD3. This phenotype characterizes cells in a transitional state during intrathymic maturation. No Fas expression modification was observed in the thymocytes from MG patients with a negative or borderline anti-AChR antibody titer. MG disease in which anti-AChR antibody is absent is unlikely to be related to thymus function. This is compatible with the absence of thymic hyperplasia and thymoma in seronegative forms of the disease, in which thymus is very often normal or involuted.2 

Possible involvement of Fashi thymocytes in the anti-AChR autoimmune response.Previous work has suggested that the autoimmune response against AChR could take place in the thymus of MG patients, given that autoreactive T cells are present10,11; in addition, thymic B lymphocytes isolated from hyperplastic thymuses can produce anti-AChR antibodies.13 Interestingly, we found that the increase in the proportion of Fashi thymocytes correlated strongly with serum anti-AChR antibody titers in MG patients. In addition, among CD4+CD8 cells, Fashi thymocytes preferentially expressed the Vβ5.1 TCR segment but not the Vβ6.7 segment. Previous studies of MG thymocytes have indicated that Vβ5.1-expressing cells are potentially autoreactive (Cohen-Kaminsky et al, manuscript submitted, January 1997) and that their proportion is enhanced among mature single-positive thymocytes and their CD3++CD4+CD8+ late precursors.39,41 Previous work on Fashi thymocytes in humans has suggested that this thymocyte subpopulation could be autoreactive.40 45 In addition, we observed that (1) Fashi cells from MG patients were responsible for the spontaneous proliferation in autologous conditions, and (2) the proliferative response of MG patient thymocytes to two different AChR peptides was abolished when Fashi cells were depleted. Altogether our findings suggest, therefore, that Fashi thymocytes comprise autoreactive T cells that induce the autoimmune response against the AChR in the MG thymus.

To identify any peripheral events associated with Fashi thymocyte accumulation, we analyzed Fas expression in peripheral lymphocytes from the same MG patients collected at the time of thymectomy. We did not observe any significant modification in CD4+Fashi or CD8+Fashi peripheral cell proportion. Therefore, Fas expression modification in MG patients was observed in the thymic but not in the peripheral compartment. Fas ligand was previously shown to play a prominent role in the elimination of autoreactive cells in the periphery26-28; thus, the increase of Fashi thymocytes proportion in MG patient thymuses could be corrected in the periphery.

Why do Fashi thymocytes accumulate in MG thymuses?The main difference we found between control and MG thymuses was the proportion of Fashi thymocytes, which was about four times (up to 10 times) higher in MG patients with positive AChR antibody titers than in controls. Masunaga et al46 found that Fas mRNA was slightly decreased in the thymus of six MG patients, but used a nonquantitative reverse transcription-polymerase chain reaction on total thymic mRNA rather than isolated thymocytes. Fas is also expressed on human thymic epithelial cells (unpublished results, January 1996), and this could explain the apparent discrepancy with our results. Further experiments comparing Fas protein and mRNA expression should involve isolated thymocytes and thymic epithelial cells.

Several hypotheses can be raised to explain the accumulation of Fashi thymocytes in MG patients. Firstly, it could be due to activated PBL reentering the thymus.47 This hypothesis is unlikely for several reasons: (1) in MG patients, the increase in Fashi cell proportion was observed in thymocytes but not in PBL; (2) the increase of Fashi cell proportion was observed not only in CD4+Fashi but also in the CD4+CD8+Fashi population that is mainly a thymic subset; and (3) Fashi PBL, but not Fashi thymocytes, are resistant to Fas-induced cell death in the absence of activation.43 

Secondly, Fashi thymocytes from control subjects and MG patients are enriched in activated cells, because they strongly express CD25 and HLA-DR. Activation of peripheral lymphocytes induces an increase in Fas expression.48 The sensitivity or resistance of activated cells to Fas-mediated apoptosis depends on the activation state.43 In addition, stimulation of human thymocytes through the TCR complex induces strong Fas expression45 (unpublished results, June 1996). Our team has previously found several signs of activation in the thymus of MG patients,10,13 especially increased cytokine expression.49 Taken together, these data suggest that the accumulation of Fashi thymocytes in MG patients is related to an increase in activation signals.

Thirdly, the accumulation of activated Fashi thymocytes could be caused by a failure to eliminate these cells in the thymus. However, most Fashi thymocytes in MG patients are sensitive to an agonistic anti-Fas antibody, showing that the Fas receptor is functional and can transduce an apoptotic signal. We could wonder whether another Fas/Fas ligand system dysfunction could be involved in the maintenance of Fashi thymocytes. Defective secretion of the Fas ligand or increased soluble Fas receptor levels could induce an accumulation of cells that normally die of apoptosis mediated by the Fas system. Cells able to produce Fas ligand are poorly characterized in the human thymus, although recent data suggest that thymic epithelial cell lines are good producers50 (unpublished results, July 1996). Soluble Fas receptor is able to inhibit Fas-mediated apoptosis, probably in interacting with available Fas ligand; its level is increased in patients with systemic lupus erythematosus according to Cheng et al,19 although other groups disagree.51,52 In addition, an increase in the level of some cytokines in MG thymuses could induce a less efficient Fas/Fas ligand-mediated cell death; indeed, it was shown that recombinant IL-12 was able to inhibit Fas-mediated apoptosis in human peripheral CD4+ lymphocytes.53 In conclusion, the accumulation of Fashi cells in MG patients could be caused by an imbalance between activation and deletion of thymic cells.

Taken together, our results indicate that a subpopulation of thymocytes strongly expressing Fas antigen may comprise AChR-reactive cells. These thymocytes, enriched in activated cells, accumulate in the thymus of MG patients with positive anti-AChR antibody titers and are not totally eliminated.

We thank Profs J.Y. Neveu and C. Planché, and Dr R. Nottin for providing normal thymuses. We are grateful to Prof A. Fisher and Dr J.M. Bertho for critical reading of the manuscript.

Supported by grants from AFM (Association Française contre les Myopathies), CNRS (Centre National de la Recherche Scientifique), and CNAMTS (Caisse Nationale d'Assurance Maladie des Travailleurs Salariés). N.M. received a postdoctoral grant from AFM.

Address reprint requests to Nathalie Moulian, PhD, Laboratoire d'Immunologie Cellulaire et Moléculaire, CNRS URA 1159, Hôpital Marie-Lannelongue, 133, avenue de la Résistance, 92350 Le Plessis Robinson, France.

1
Lindstrom
JM
Seybold
ML
Lennon
VA
Whittingham
S
Duane
DD
Antibody to acetylcholine receptor in myasthenia gravis: Prevalence, clinical correlates, and diagnostic value.
Neurology (Minneap)
26
1976
1054
2
Berrih-Aknin
S
Morel
E
Raimond
F
Safar
D
Gaud
C
Binet
JP
Levasseur
P
Bach
JP
The role of the thymus in myasthenia gravis. Immunohistological and immunological studies in 115 cases.
Ann NY Acad Sci
505
1987
50
3
Berrih
S
Morel
E
Gaud
C
Raimond
F
Le Brigand
H
Bach
JF
Anti-AChR antibodies, thymic histology, and T cell subsets in myasthenia gravis.
Neurol
34
1984
66
4
Mulder
DG
Graves
M
Herrmann
C
Thymectomy for myasthenia gravis: Recent observations and comparisons with past experience.
Ann Thorac Surg
48
1989
551
5
Molnar
J
Szobor
A
Myasthenia gravis: Effect of thymectomy in 425 patients. A 15-year experience.
Eur J Cardiothorac Surg
4
1990
8
6
Kuks
JB
Oosterhuis
HJ
Limburg
PC
The
TH
Anti-acetylcholine receptor antibodies decrease after thymectomy in patients with myasthenia gravis. Clinical correlations.
J Autoimmunity
4
1991
197
7
Kuks
JB
Oosterhuis
HJ
Limburg
PC
The
TH
Antibodies to acetylcholine receptors in myasthenia gravis. In vitro synthesis by peripheral blood lymphocytes before and after thymectomy.
Clin Exp Immunol
87
1992
246
8
Willcox
N
Newsom-Davis
J
Calder
LR
Cell types for anti-acetylcholine receptor antibody by cultured thymocytes and blood lymphocytes in myasthenia gravis.
Clin Exp Immunol
58
1984
97
9
Safar
D
Berrih-Aknin
S
Morel
E
In vitro anti-acetylcholine receptor antibody synthesis by myasthenia gravis patient lymphocytes: Correlation with thymic histology and thymic epithelial-cell interactions.
J Clin Immunol
7
1987
225
10
Melms
AS
Chreste
BCG
Schalke
H
Wekerle
H
Mauron
A
Ballivet
M
Barkas
T
Autoimmune T lymphocytes in myasthenia gravis: determination of target epitopes using T lines and recombinant products of the mouse nicotinic acetylcholine receptor gene.
J Clin Invest
83
1989
785
11
Sommer
N
Willcox
N
Harcourt
GC
Newsom-Davies
J
Myasthenic thymus and thymoma are selectively enriched in acetylcholine receptor-reactive T cells.
Ann Neurol
28
1990
312
12
Cohen-Kaminsky
S
Levasseur
P
Binet
JP
Berrih-Aknin
S
Evidence of enhanced recombinant interleukin-2 sensitivity in thymic lymphocytes from patients with myasthenia gravis: Possible role in autoimmune pathogenesis.
J Neuroimmunol
24
1989
75
13
Leprince
C
Cohen-Kaminsky
S
Berrih-Aknin
S
Vernet der Garabedian
B
Treton
D
Galanaud
P
Richard
Y
Thymic B cells from myasthenia gravis patients are activated B cells: Phenotypic and functional analysis.
J Immunol
145
1990
2115
14
Von Boehmer
H
The selection of α-β heterodimeric T cell receptor for antigen.
Immunol Today
7
1986
333
15
Surh
CD
Sprent
J
T-cell apoptosis detected in situ during positive and negative selection in the thymus.
Nature
372
1994
100
16
Nossal
GJV
Negative selection of lymphocytes.
Cell
76
1994
229
17
Webb
S
Morris
C
Sprent
J
Extrathymic tolerance of mature T cells: Clonal elimination as a consequence of immunity.
Cell
63
1990
1249
18
Nagata
S
Suda
T
Fas and Fas ligand: lpr and gld mutations.
Immunol Today
16
1995
39
19
Cheng
J
Zhou
T
Liu
C
Shapiro
JP
Brauer
MJ
Kiefer
MC
Barr
PJ
Mountz
JD
Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule.
Science
263
1994
1759
20
Mysler
E
Bini
P
Drappa
J
Ramos
P
Friedman
SM
Krammer
PH
Elkon
KB
The apoptosis-1/Fas protein in human systemic lupus erythematosus.
J Clin Invest
93
1994
1029
21
Ohsako
S
Hara
M
Harigai
M
Fukasawa
C
Kashiwasaki
S
Expression and function of Fas antigen and bcl-2 in human systemic erythematosus lymphocytes.
Clin Immunol Immunopathol
73
1994
109
22
Amasaki
Y
Kobayashi
S
Takeda
T
Ogura
N
Jodo
S
Nakabayashi
T
Tsutsumi
A
Fujisaku
A
Koike
T
Up-regulated expression of Fas antigen (CD95) by peripheral naive and memory T cell subsets in patient with systemic lupus erythematosus (SLE): A possible mechanism for lymphopenia.
Clin Exp Immunol
99
1995
245
23
Fisher
GH
Rosenberg
FJ
Staus
SE
Dale
JK
Middelton
LA
Lin
AY
Strober
W
Lenardo
MJ
Puck
JM
Dominant interfering Fas gene mutations impair apoptosis in a human lymphoproliferative syndrome.
Cell
81
1995
935
24
Rieux-Laucat
F
Le Deist
F
Hivroz
C
Roberts
LAG
Debatin
KM
Fisher
A
de Villartay
JP
Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity.
Science
268
1995
1347
25
Kägi
D
Vignaux
F
Ledermann
B
Bürki
K
Depraetere
V
Nagata
S
Hengartner
H
Golstein
P
Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity.
Science
265
1994
528
26
Dhein
J
Walczak
H
Bäumler
C
Debatin
KM
Krammer
PH
Autocrine T-cell suicide mediated by APO-1/(Fas/CD95).
Nature
373
1995
438
27
Brunner
T
Mogil
RG
LaFace
D
Yoo
NJ
Mahboubi
A
Echeverri
F
Martin
SJ
Force
WR
Lynch
DH
Ware
CH
Green
DR
Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas.
Nature
373
1995
441
28
Ju
ST
Panka
DJ
Cui
H
Ettinger
R
El-Khatib
M
Sherr
DH
Stanger
BZ
Marshak-Rothstein
A
Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation.
Nature
373
1995
444
29
Watanabe-Fukunaga
R
Brannan
CI
Copeland
NG
Jenkins
NA
Nagata
S
Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis.
Nature
356
1992
314
30
Singer
GG
Abbas
AK
The Fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice.
Immunity
1
1994
365
31
Adachi
M
Suematsu
S
Suda
T
Watanabe
D
Fukuyama
H
Ogasawara
J
Tanaka
T
Yoshida
N
Nagata
S
Enhanced and accelerated lymphoproliferation in Fas-null mice.
Proc Natl Acad Sci USA
93
1996
2131
32
Zhou
T
Bluethmann
H
Eldridge
J
Berry
K
Mountz
JD
Origin of CD4−CD8−B220+ T cells in MRL-lpr/lpr mice.
J Immunol
8
1993
3651
33
Mariani
SM
Matiba
B
Armandola
EA
Krammer
PH
The APO-1/Fas (CD95) receptor is expressed in homozygous MRL/lpr mice.
Eur J Immunol
24
1994
3119
34
Ogasawara
J
Suda
T
Nagata
S
Selective apoptosis of CD4+CD8+ thymocytes by the anti-Fas antibody.
J Exp Med
181
1995
485
35
Fisher
GH
Lenardo
MJ
Zuniga-Pflucker
JC
Synergy between T cell receptor and Fas (CD95/APO-1) signaling in mouse thymocyte death.
Cell Immunol
169
1996
99
36
Levine
G
Rosai
J
Thymic hyperplasia and neoplasia: A review of current concepts.
Hum Pathol
9
1978
495
37
Lindstrom
J
An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis.
Clin Immunol Immunopathol
7
1977
36
38
Voltz
R
Hohlfeld
R
Fateh-Moghadam
A
Witt
TN
Wick
M
Reimers
C
Siegele
B
Wekerle
H
Myasthenia gravis: Measurement of anti-AChR autoantibodies using cell line TE671.
Neurology
41
1991
1836
39
Berrih-Aknin
S
Cohen-Kaminsky
S
Truffault
T
T-cell receptor expression in the thymus from patients with myasthenia gravis.
Ann NY Acad Sci
756
1995
438
40
Debatin
KM
Süss
D
Krammer
PH
Differential expression of APO-1 on human thymocytes: Implications for negative selection?
Eur J Immunol
24
1994
753
41
Truffault T, Cohen-Kaminsky S, Khalil I, Levasseur P, Berrih-Aknin S: Altered intrathymic T cell repertoire in human myasthenia gravis. Ann Neurol February 1997 (in press)
42
Berrih-Aknin
S
Cohen-Kaminsky
S
Lepage
V
Neumann
D
Bach
JF
Fuchs
S
T-cell antigenic sites involved in myasthenia gravis: Correlations with antibody titre and disease severity.
J Autoimmunity
4
1991
137
43
Klas
C
Debatin
KM
Jonker
RR
Krammer
PH
Activation interferes with the APO-1 pathway in mature human T cells.
Int Immunol
5
1993
625
44
Miyawaki
T
Uehara
T
Nibu
R
Tsuji
T
Yachie
A
Yonehara
S
Taniguchi
N
Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood.
J Immunol
149
1992
3753
45
Yonehara
S
Nishimura
Y
Kishil
S
Yonehara
M
Takazawa
K
Tamatani
T
Ishii
A
Involvement of apoptosis antigen Fas in clonal deletion of human thymocytes.
Int Immunol
6
1994
1849
46
Masunaga
A
Arai
T
Yoshitake
T
Itoyama
S
Sugawara
I
Reduced expression of apoptosis-related antigens in thymuses from patients with myasthenia gravis.
Immunol Lett
39
1994
169
47
Agus
DB
Surh
CD
Sprent
J
Reentry of T cells to the adult thymus is restricted to activated T cells.
J Exp Med
173
1991
1039
48
Owen-Schaub
LB
Yonehara
S
Crump
III WL
Grimm
EA
DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement.
Cell Immunol
140
1992
197
49
Emilie
D
Crevon
MC
Cohen-Kaminsky
S
Peuchmaur
M
Devergne
O
Berrih-Aknin
S
Galanaud
P
In situ production of interleukins in hyperplastic thymus from myasthenia gravis patients.
Hum Pathol
22
1991
461
50
Lalor DJ, Hayashi J: Expression of Fas ligand by thymic epithelial cells. The 9th International Congress of Immunology. San Francisco, CA, 1995, p 743 (abstr)
51
Knipping
E
Krammer
PH
Onel
KB
Lehman
TJA
Mysler
E
Elkon
KB
Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis.
Arthritis Rheum
38
1995
1735
52
Goel
N
Ulrich
DT
StClair
EW
Fleming
JA
Lynch
DH
Seldin
MF
Lack of correlation between serum soluble Fas/Apo-1 levels and autoimmune disease.
Arthritis Rheum
38
1995
1738
53
Estaquier
J
Idziorek
T
Zou
W
Emilie
D
Farber
CM
Bourez
JM
Ameisen
JC
T helper type 1/T helper type 2 cytokines and T cell death: Preventive effect of interleukin 12 on activation-induced and CD95 (FAS/APO-1)-mediated apoptosis of CD4+ T cells from human immunodeficiency virus-infected persons.
J Exp Med
182
1995
1759
Sign in via your Institution